SCHEMBL23950998

SCHEMBL23950998

Cn1cc(-c2nc(-c3ccc(Cl)cc3)cc3c(=O)n(-c4cccc(O)c4)cnc23)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 3/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
FGFR3 P22607 3/20 0.35
KDR P35968 2/20 0.35
MCHR1 Q99705 3/20 0.35
FGFR1 P11362 2/20 0.35
FGFR2 P21802 2/20 0.35
CREBBP Q92793 1/20 0.35
FGFR4 P22455 1/20 0.35
MAT2A P31153 1/20 0.35
AURKB Q96GD4 1/20 0.34
HSP90AA1 P07900 1/20 0.34
SSTR2 P30874 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PIM1 P11309 1/20 0.34
GRM1 Q13255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23950750 0.89 HSP90AA1 (0.38) FYNESR1ESR2FGFR3FGFR1
SCHEMBL30101833 0.89 HSP90AA1 (0.38) FYNESR1ESR2FGFR3FGFR1
SCHEMBL23925506 0.84 MAPT (0.44) FYNESR1ESR2MCHR1GRM1
SCHEMBL30101933 0.84 MAPT (0.44) FYNESR1ESR2MCHR1GRM1
SCHEMBL23950561 0.82 BRD4 (0.43) CNR1CNR2FGFR3KDRMEN1
SCHEMBL23390407 0.79 PIM1 (0.42) CNR1CNR2FGFR3KDRMCHR1
SCHEMBL23390159 0.78 FGFR3 (0.38) CNR1CNR2FGFR3KDRAURKB
SCHEMBL23390162 0.78 FGFR3 (0.38) CNR1CNR2FGFR3KDRAURKB
SCHEMBL23390288 0.78 FGFR3 (0.38) CNR1CNR2FGFR3KDRAURKB
SCHEMBL23390448 0.77 AHR (0.42) CNR1CNR2FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 FYN 1546/4885ESR1 234/4885ESR2 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.